Trialbee and Castor partner to simplify enrolment to clinical trials globally

Trialbee and Castor partner to simplify enrolment to clinical trials globally

By: IPP Bureau

Last updated : September 23, 2021 11:27 am



Industry leaders to increase patient access to clinical research and scale remote enrollment of participants for trial sponsors to promote increased health equity


Trialbee, the leading enrolment performance company, and Castor, a leading provider of decentralized and hybrid clinical trial solutions, announced a strategic partnership to accelerate patient enrolment, optimise patient engagement, and reduce site burden for clinical trials globally.

Castor and Trialbee’s logical integration allows sponsors to meet enrollment timelines with continuous access to all their study data. Together, the fast-growing companies will expedite patient recruitment and streamline clinical trials through advanced data science and streamlined workflows for patient enrollment, data collection, and engagement. The partnership will diversify patient participation and improve equitable health outcomes for global decentralized and hybrid clinical programs.

“We are excited to partner with Trialbee to improve patient engagement, as well as optimize patient diversity and study inclusivity with real-time insights around patient demographics across all recruitment channels,” said Derk Arts, M.D., PhD, CEO & Founder, Castor. “Our partnership provides sponsors a seamless decentralized and hybrid clinical trial solution to manage all their clinical trial touchpoints and expand inclusivity at a global scale.”

Recruiting and retaining qualified clinical trial participants is increasingly difficult as clinical study designs become more complex. With Trialbee and Castor’s proven integrations, clinical trial sponsors can seamlessly manage all clinical trial touchpoints while ensuring data quality every step of the way.

“Over 70 per cent of potential clinical trial participants live more than two hours away from a trial site, increasing the need for greater scale and reach in patient awareness for today’s trial designs,” said Matt Walz, Chief Executive Officer at Trialbee.

 

Trialbee Castor Derk Arts Matt Walz

First Published : September 22, 2021 12:00 am